Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P05111: Variant p.Arg60Leu

Inhibin alpha chain
Gene: INHA
Feedback?
Variant information Variant position: help 60 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Arginine (R) to Leucine (L) at position 60 (R60L, p.Arg60Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and hydrophobic (L) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help Found in a patient with early-onset epithelial ovarian tumor; uncertain significance; alters the ratio of secreted activins and ihibins. Any additional useful information about the variant.


Sequence information Variant position: help 60 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 366 The length of the canonical sequence.
Location on the sequence: help ALGPPAVTREGGDPGVRRLP R RHALGGFTHRGSEPEEEEDV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         ALGPPAVTREGGDPGVRRLPRRHALGGFTHRGSEPEEEEDV

Mouse                         ALGPPAMDGEGGDPGIRRLPRRHAVGGFMHRTSEP-EEEDV

Rat                           ALGPPAMDGEGGGPGIRRLPRRHALGGFMHRTSEP-EEEDV

Pig                           ALGPPAVTGEGGDPGVRRLPRRHAVGGFMRRGSEP-EEEDV

Bovine                        ALGPPPVTGEGGDPGVRRLHRRHAVGGFMRRGSEP-EDQDV

Horse                         ALGPPAVTGEGGDPGVRRLPRRHALGGFARRGSEP-EEEDV

Chicken                       HLSPPAMQEPQKD--VRRVHRRDVLEEV---EVPPEEQEDT

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Propeptide 19 – 61
Mutagenesis 60 – 61 RR -> AA. Loss of cleavage; when associated with 55-AA-56.



Literature citations
Germline mutations of inhibins in early-onset ovarian epithelial tumors.
Tournier I.; Marlin R.; Walton K.; Charbonnier F.; Coutant S.; Thery J.C.; Charbonnier C.; Spurrell C.; Vezain M.; Ippolito L.; Bougeard G.; Roman H.; Tinat J.; Sabourin J.C.; Stoppa-Lyonnet D.; Caron O.; Bressac-de Paillerets B.; Vaur D.; King M.C.; Harrison C.; Frebourg T.;
Hum. Mutat. 35:294-297(2014)
Cited for: VARIANT LEU-60; CHARACTERIZATION OF VARIANT LEU-60;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.